Vnitr Lek 2022, 68(4):234-239 | DOI: 10.36290/vnl.2022.049

Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease - where they are effective and where they are not

Dalibor Musil
Interní a kardiologická klinika Fakultní nemocnice Ostrava a LF Ostravské univerzity

The article provides an overview of the development of recommendations for indications of venoactive drugs for treating symptoms and signs associated with chronic venous disease (CVD). Venoactive drugs may be beneficial in patients with subjective problems and/or swelling of the lower limbs, after surgery for varicose veins, in chronic venous insufficiency or in microcirculatory disorders. They are not indicated in asymptomatic patients with CVD, in the prevention of varicose veins or to prevent their progression. Drugs with proven efficacy in clinical trials should be preferred.

Keywords: venoactive drugs, pentoxifylline, sulodexide, randomized controlled trials, strenght of recommendation, level of evidence, GRADE, symptomatic treatment.

Published: June 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil D. Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease - where they are effective and where they are not. Vnitr Lek. 2022;68(4):234-239. doi: 10.36290/vnl.2022.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Roztočil K. Venotonika - komu a která? s. 51 - 53, In: Broulíková A, Bulvas M, Karetová D. Angiologie 2007, trendy soudobé angiologie. Praha: Galen; 2007, 105 s.
    2. Martinez MJ, Bonfill X, Moreno RM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005: CD003229.
    3. Ramelet AA, Boisseau MR, Allegra C, Nikolaies A et al. Veno‑active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc. 2005;33:309-319.
    4. Coleridge‑Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta‑analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198-208. Go to original source... Go to PubMed...
    5. Jull AB, Arroll B, Parag W, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012; 12: CD001733. Go to original source... Go to PubMed...
    6. Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. Cochrane Database of Systemic Reviews. 2016, issue 6. Art. No: CD010694. Go to original source...
    7. Cocceri S, Bignamini AA. Pharmacological adjuncts for chronic venous ulcer healing. Phlebology. 2016;31:366-367. Go to original source... Go to PubMed...
    8. Paseerrin M, Ramelet AA. Pharmacological treatment of primary venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011; 41: 117-125. Go to original source... Go to PubMed...
    9. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLIty of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53:245-256. Go to original source... Go to PubMed...
    10. Zapater P, Horga JF, Garcia A. Risk of drug‑induced agranulocytosis: the case of calcium dobesilate. Eur J Clin Pharmacol. 2000;58:767-772. Go to original source... Go to PubMed...
    11. Allaert FA. Meta‑analysis of the impact of the principal venoactice drugs agents on malleolar venous edema. Int Angiol. 2012;31:310-315. Go to PubMed...
    12. Allaert FA, Hugue C, Cazaubon M et al. Correlation between improvement in fuctional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort). Int Angiol. 2011;30:272-277. Go to PubMed...
    13. Rabe E, Jaeger KA, Bulitta M, Panier F. Calcium dobesilate in patients suffering from venous insufficiency: a double‑blind, placebo‑controlled, clinical trial. Phlebology. 2011;26:162-168. Go to original source... Go to PubMed...
    14. Labs KH, Degisher S, Gamba G et al. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized double‑blind, placebo‑controlled trial. Phlebology. 2004;19:123-130. Go to original source...
    15. Flota‑Cervera F, Flota‑Ruiz CF, Trevino C, Berber A. Randomized, double‑blind, placebo‑controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology. 2008;59:352-356. Go to original source... Go to PubMed...
    16. Martínez‑Zapata MJ, Moreno RM, Gich I et al. A randomized, double‑blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg. 2008;35:358-365. Go to original source... Go to PubMed...
    17. Nicolaides A, Kakkos S, Baekgaard N et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37:232-254. Go to original source... Go to PubMed...
    18. Perrin M, Eklof B, VAN Rij A et al. Venous symptoms: the SYM Vein Consensus statement developer under the auspices of the European Venous Forum. Int Agiol. 2016;35:374-398.
    19. De Souza MGC, Cyrino FZ, Mayal M et al. Beneficial effect of the micronized purified flavonoid fraction (MPFF, Daflon 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology. 2016;31:50-56. Go to original source... Go to PubMed...
    20. Bogachev VY, Boldin BV, Lobanov VN. Benefit of micronized purified flavonoid fraction as adjuvant therapy on the inflammatory response after sclerotherapy. Int Angiol. 2018; 37: 71-78. Go to original source... Go to PubMed...
    21. Mazzaccaro D, Muzzarelli I, Modafferi A et al. Use of venoactive drugs after surgery for varicose veins: a preliminary study. Int Angiol. 2018;37:79-84. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.